{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:00:09Z","timestamp":1753891209348,"version":"3.41.2"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>ABO blood group system is the most important blood group system in transfusion and transplantation medicine. Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphomas (NHLs) worldwide. There have been some studies that lymphoma could affect ABO blood group system and thus affect blood transfusion strategy. However, the mechanisms lymphoma affecting ABO blood group system have not been fully elucidated so far. Here, we report a case of a patient who was a 72-year-old Chinese man came to our hospital for medical advice because of cervical lymphadenophathy. The patient was subsequently diagnosed with diffuse large B-cell lymphoma by lymph-node biopsy. His ABO blood group was initially typed as B on November 7, 2020. He was transfusing B type leukocyte poor RBCs (LPR) before we found the patient\u2019s ABO blood group discrepancy on December 2, 2020 by forward and reverse typing methods, which the discrepancy was verified by genotyping. The patient began to transfuse O type washed RBCs (WRBC) since then. Compared to transfuse B type leukocyte poor RBCs (LPR), the efficiency of transfusing O type washed RBCs (WRBC) was better. Although hemoglobin level did not greatly improve, indirect bilirubin level evidently decreased. Furthermore, we found B-cell lymphoma affected blood transfusion strategy by producing IgM anti-B antibody in this case. Clinicians should need to be aware of the effect of B-cell lymphoma on blood transfusion strategy.<\/jats:p>","DOI":"10.3389\/fmed.2022.904296","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T04:55:10Z","timestamp":1652676910000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["B-Cell Lymphoma Producing IgM Anti-B Antibody: A Case Report"],"prefix":"10.3389","volume":"9","author":[{"given":"Feiyu","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiejun","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingjian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2450\/2013.0152-13","article-title":"Beyond immunohaematology: the role of the ABO blood group in human diseases.","volume":"11","author":"Liumbruno","year":"2013","journal-title":"Blood Transfus."},{"key":"B2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3109\/10408363.2012.708647","article-title":"ABO blood group, hypercoagulability, and cardiovascular and cancer risk.","volume":"49","author":"Franchini","year":"2012","journal-title":"Crit Rev Clin Lab Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1515\/cclm-2013-0168","article-title":"ABO blood group: old dogma, new perspectives.","volume":"51","author":"Franchini","year":"2013","journal-title":"Clin Chem Lab Med."},{"key":"B4","article-title":"ABO blood groups and cardiovascular diseases.","volume":"2012","author":"Zhang","year":"2012","journal-title":"Int J Vasc Med."},{"key":"B5","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms.","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.3324\/haematol.2016.148809","article-title":"Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin lymphoma classification project.","volume":"101","author":"Perry","year":"2016","journal-title":"Haematologica."},{"key":"B7","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes.","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin."},{"key":"B8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/path.1485","article-title":"Differential emu enhancer activity and expression of BOB.1\/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas.","volume":"202","author":"Loddenkemper","year":"2004","journal-title":"J Pathol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/ajcp\/71.4.473","article-title":"In-vitro synthesis of an anti-BI cold agglutinin complicating a case of lymphoma.","volume":"71","author":"Dodds","year":"1979","journal-title":"Am J Clin Pathol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jclinepi.2017.04.026","article-title":"CARE guidelines for case reports: explanation and elaboration document.","volume":"89","author":"Riley","year":"2017","journal-title":"J Clin Epidemiol."},{"key":"B11","first-page":"136","author":"Harmening","year":"2013","journal-title":"Modern Blood Banking and Transfusion Practice."},{"key":"B12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000025260","article-title":"Coexisting anti-I\/i plus anti Pr cold agglutinins in individual sera.","volume":"27","author":"Roelcke","year":"2000","journal-title":"Infusionsther Transfusionsmed."},{"key":"B13","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/j.1423-0410.2009.01291.x","article-title":"Distribution of ABO blood group allele and identification of three novel alleles in the Chinese Han population.","volume":"98","author":"Zhu","year":"2010","journal-title":"Vox Sang."},{"key":"B14","doi-asserted-by":"publisher","first-page":"D1023","DOI":"10.1093\/nar\/gkr958","article-title":"BGMUT: NCBI dbRBC database of allelic variations of genes encoding antigens of blood group systems.","volume":"40","author":"Patnaik","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1182\/blood-2003-03-0955","article-title":"The nature of diversity and diversification at the ABO locus.","volume":"102","author":"Seltsam","year":"2003","journal-title":"Blood."},{"key":"B16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1046\/j.1537-2995.2003.00321.x","article-title":"Systematic analysis of the ABO gene diversity within exons 6 and 7 by PCR screening reveals new ABO alleles.","volume":"43","author":"Seltsam","year":"2003","journal-title":"Transfusion."},{"key":"B17","first-page":"83","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview.","volume":"102","author":"Sabattini","year":"2010","journal-title":"Pathologica."},{"key":"B18","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/PPO.0b013e31826aee97","article-title":"The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification.","volume":"18","author":"Menon","year":"2012","journal-title":"Cancer J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2147\/ott.s3322","article-title":"Expanded use of rituximab in the management of non-Hodgkin lymphoma.","volume":"2","author":"Eichenauer","year":"2009","journal-title":"Onco Targets Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.leukres.2015.11.001","article-title":"Targeting B-cell non Hodgkin lymphoma: new and old tricks.","volume":"42","author":"Solimando","year":"2016","journal-title":"Leuk Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the groupe d\u2019etudes des lymphomes de l\u2019adulte.","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","article-title":"Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.","volume":"17","author":"van Dongen","year":"2003","journal-title":"Leukemia."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.904296\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T04:55:17Z","timestamp":1652676917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.904296\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":22,"alternative-id":["10.3389\/fmed.2022.904296"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.904296","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2022,5,16]]},"article-number":"904296"}}